Pathfinder Cell Therapy Inc (PFND) 股票價格預測

Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company. The company is headquartered in Cambridge, Massachusetts. The firm is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The firm is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The firm has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The firm has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.